Theriva Biologics, Inc. (TOVX)
USD 1.15
(-3.36%)
USD 1.15
(-3.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -135 Thousand USD | 49.63% |
| 2022 | -268 Thousand USD | -208.05% |
| 2021 | -87 Thousand USD | 56.72% |
| 2020 | -201 Thousand USD | 16.25% |
| 2019 | -240 Thousand USD | 11.76% |
| 2018 | -272 Thousand USD | -11.02% |
| 2017 | -245 Thousand USD | -56.05% |
| 2016 | -157 Thousand USD | -118.06% |
| 2015 | -72 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | -100.0% |
| 2010 | 2.69 Million USD | 2516.08% |
| 2009 | 103.08 Thousand USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2002 | 10 Thousand USD | -98.86% |
| 2001 | 874.09 Thousand USD | 125.4% |
| 2000 | 387.79 Thousand USD | 23.88% |
| 1999 | 313.03 Thousand USD | 4.35% |
| 1998 | 300 Thousand USD | -25.0% |
| 1997 | 400 Thousand USD | 0.0% |
| 1996 | 400 Thousand USD | 300.0% |
| 1995 | 100 Thousand USD | 0.0% |
| 1994 | 100 Thousand USD | 0.0% |
| 1993 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -38 Thousand USD | 2.56% |
| 2024 Q1 | -39 Thousand USD | -105.42% |
| 2023 Q4 | 719 Thousand USD | 636.57% |
| 2023 Q3 | -134 Thousand USD | -2.29% |
| 2023 Q1 | -114 Thousand USD | -356.0% |
| 2023 Q2 | -131 Thousand USD | -14.91% |
| 2023 FY | -135 Thousand USD | 49.63% |
| 2022 Q4 | -25 Thousand USD | -4.17% |
| 2022 Q3 | -24 Thousand USD | -33.33% |
| 2022 Q2 | -18 Thousand USD | 0.0% |
| 2022 Q1 | -18 Thousand USD | -38.46% |
| 2022 FY | -268 Thousand USD | -208.05% |
| 2021 Q4 | -13 Thousand USD | 27.78% |
| 2021 FY | -87 Thousand USD | 56.72% |
| 2021 Q1 | -33 Thousand USD | 0.0% |
| 2021 Q2 | -23 Thousand USD | 30.3% |
| 2021 Q3 | -18 Thousand USD | 21.74% |
| 2020 FY | -201 Thousand USD | 16.25% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | -240 Thousand USD | 11.76% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 FY | -272 Thousand USD | -11.02% |
| 2018 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | -245 Thousand USD | -56.05% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | -157 Thousand USD | -118.06% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | -72 Thousand USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 100.0% |
| 2011 Q1 | 79.28 Thousand USD | -47.86% |
| 2011 Q2 | 54.42 Thousand USD | -31.36% |
| 2011 Q3 | 32.54 Thousand USD | -40.21% |
| 2011 Q4 | -166.24 Thousand USD | -610.88% |
| 2011 FY | - USD | -100.0% |
| 2010 Q1 | 60.03 Thousand USD | 15.45% |
| 2010 FY | 2.69 Million USD | 2516.08% |
| 2010 Q2 | 2.19 Million USD | 3555.77% |
| 2010 Q4 | 152.06 Thousand USD | -47.55% |
| 2010 Q3 | 289.89 Thousand USD | -86.79% |
| 2009 Q3 | 51.08 Thousand USD | 0.0% |
| 2009 FY | 103.08 Thousand USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | 52 Thousand USD | 1.8% |
| 2008 FY | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2003 Q1 | 75 Thousand USD | 0.0% |
| 2002 Q3 | - USD | -100.0% |
| 2002 FY | 10 Thousand USD | -98.86% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | 10 Thousand USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | -100.0% |
| 2001 Q2 | 693.34 Thousand USD | 283.6% |
| 2001 Q1 | 180.74 Thousand USD | -6.17% |
| 2001 FY | 874.09 Thousand USD | 125.4% |
| 2001 Q4 | - USD | 0.0% |
| 2000 Q1 | 90.15 Thousand USD | -71.2% |
| 2000 Q4 | 192.63 Thousand USD | 1392.14% |
| 2000 Q3 | 12.91 Thousand USD | -85.98% |
| 2000 Q2 | 92.09 Thousand USD | 2.15% |
| 2000 FY | 387.79 Thousand USD | 23.88% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1999 FY | 313.03 Thousand USD | 4.35% |
| 1999 Q1 | 100 Thousand USD | 0.0% |
| 1999 Q4 | 313.03 Thousand USD | 0.0% |
| 1999 Q3 | - USD | -100.0% |
| 1998 Q3 | 100 Thousand USD | -75.0% |
| 1998 Q4 | - USD | -100.0% |
| 1998 FY | 300 Thousand USD | -25.0% |
| 1998 Q2 | 400 Thousand USD | 300.0% |
| 1998 Q1 | 100 Thousand USD | -75.0% |
| 1997 Q4 | 400 Thousand USD | 300.0% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q1 | 100 Thousand USD | 200.0% |
| 1997 FY | 400 Thousand USD | 0.0% |
| 1997 Q3 | 100 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 Q4 | -100 Thousand USD | -120.0% |
| 1996 Q3 | 500 Thousand USD | 400.0% |
| 1996 FY | 400 Thousand USD | 300.0% |
| 1995 Q4 | - USD | -100.0% |
| 1995 Q1 | 100 Thousand USD | 0.0% |
| 1995 FY | 100 Thousand USD | 0.0% |
| 1995 Q2 | 100 Thousand USD | 0.0% |
| 1995 Q3 | 100 Thousand USD | 0.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 FY | 100 Thousand USD | 0.0% |
| 1994 Q4 | - USD | -100.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1993 Q4 | - USD | -100.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ADC Therapeutics SA | 67.02 Million USD | 100.201% |
| Alto Neuroscience, Inc. | -373 Thousand USD | 63.807% |
| Annovis Bio, Inc. | - USD | Infinity% |
| Biohaven Pharmaceutical Holding Company Ltd. | -3.36 Million USD | 95.993% |
| Ginkgo Bioworks Holdings, Inc. | 197.45 Million USD | 100.068% |
| Nuvation Bio Inc. | -222 Thousand USD | 39.189% |
| Nuvation Bio Inc. | -222 Thousand USD | 39.189% |
| Arcus Biosciences, Inc. | -223 Million USD | 99.939% |
| Zymeworks Inc. | -66.97 Million USD | 99.798% |